Global AI-based Clinical Trial Solutions Market Projected to Reach $5.65 Billion by 2028
April 01, 2024 18:04 ET
|
Research and Markets
Dublin, April 01, 2024 (GLOBE NEWSWIRE) -- The "AI-based Clinical Trial Solution Providers Global Market Report 2024" report has been added to ResearchAndMarkets.com's offering. Market Growth...
Clinical Trial Supplies Market Report 2024-2034 - Rising Demand for Biologics Propelling Growth of Cold Chain Distribution Supplies
March 29, 2024 05:20 ET
|
Research and Markets
Dublin, March 29, 2024 (GLOBE NEWSWIRE) -- The "Clinical Trial Supplies Market Report 2024-2034" report has been added to ResearchAndMarkets.com's offering.World revenue for the Clinical Trial...
Global Clinical Trial Supply & Logistics Market for Pharmaceutical Industry Poised for Growth, Reaching USD 6.9 Billion by 2028
March 27, 2024 13:13 ET
|
Research and Markets
Dublin, March 27, 2024 (GLOBE NEWSWIRE) -- The "Global Clinical Trial Supply & Logistics for Pharmaceutical Industry Market (2023-2028) Competitive Analysis, Impact of Economic Slowdown &...
Alterity Therapeutics Receives a A$3.9 Million Research & Development Tax Incentive Refund
March 26, 2024 10:25 ET
|
ALTERITY THERAPEUTICS LIMITED
MELBOURNE, Australia and SAN FRANCISCO, March 27, 2024 (GLOBE NEWSWIRE) -- Alterity Therapeutics Limited (ASX: ATH, NASDAQ: ATHE) (“Alterity” or “the Company”), a biotechnology company...
PharmAla Biotech Signs Sale Agreement with Numinus
March 26, 2024 08:55 ET
|
PharmAla Biotech
PharmAla announces binding sales order from Numinus Wellness, as well as a recent presentation of data to the Behaviour, Biology, and Chemistry Conference
Healis Therapeutics announces collaboration with Massachusetts General Hospital (MGH) and affiliates of Harvard Medical School to advance clinical-stage neuroscience research
March 26, 2024 08:00 ET
|
Healis Therapeutics
The collaboration will focus on Healis’ clinical program studying the safety and efficacy of CKDB-501A, a BoNT/A neuromodulator, for neuropsychiatry.
First patient in the UK is dosed in the OATD-01 Phase 2 KITE study in pulmonary sarcoidosis
March 22, 2024 04:00 ET
|
Molecure
- OATD-01 is an innovative, first-in-class chitinase inhibitor for the treatment of sarcoidosis among other diseases where chronic inflammation leads to tissue remodeling and fibrosis - In the...
Global Clinical Trial Supplies Market Report 2024-2028 & 2033: New Real-World Evidence Technologies Emerging, Impacting Healthcare Strategy Formulation and Drug Development
March 20, 2024 13:04 ET
|
Research and Markets
Dublin, March 20, 2024 (GLOBE NEWSWIRE) -- The "Clinical Trial Supplies Global Market Report 2024" report has been added to ResearchAndMarkets.com's offering. The specialized field of clinical...
Quoin Pharmaceuticals Provides Corporate Update and Announces Fourth Quarter and 2023 Financial Results
March 13, 2024 16:05 ET
|
Quoin Pharmaceuticals, Inc.
Company reported positive initial clinical data for QRX003 from first six evaluable subjects in ongoing open-label Netherton Syndrome study with positive benefits observed across a number of clinical...
Global Clinical Trials Connect Conference 2024: Discussions on the Futuristic Advancements in Clinical Trials and Clinical Research - London, United Kingdom - May 28-29, 2024 - Registration Now Open
March 13, 2024 11:21 ET
|
Research and Markets
Dublin, March 13, 2024 (GLOBE NEWSWIRE) -- The "Global Clinical Trials Connect 2024" conference has been added to ResearchAndMarkets.com's offering. The Global Clinical Trials Connect 2024 will...